Friday, 27 March 2015
On Wednesday, March 25, 2015 at the Croatian Institute for Brain Research Amy Lam, PhD Head of Business Development BioQuartera the University of Edinburgh gave a lecture entitled "Translational regenerative medicine and neuroscience research at Edinburgh". The next day, on Thursday, March 26, 2015 at the premises of School of Medicine University of Zagreb, she held another lecture entitled "Encouraging a more translational medical research culture at Edinburgh". In both lectures Amy Lam spoke of experiences of their successful team in the commercialization of research results through collaboration with industry and encouraging a new approach to knowledge transfer.
Amy Lam joined Edinburgh BioQuarter in November 2011 as part of the Business Development team, with the objective of facilitating commercial engagement of the research base with pharma and biotech and supporting the commercialisation of technologies arising from the College of Medicine and Veterinary Medicine at the University of Edinburgh and NHS Lothian. The Business Development team work with academic scientists, clinical practitioners and health professionals to develop deeper links with industry, to collaborate and accelerate the development of new drugs, diagnostic tools and medical devices to diagnose and treat diseases.
Prior to her role at BioQuarter, Amy has held a number of positions specialising in the commercialisation of technologies in the life sciences sector since 2001. Amy has worked in academia and in industry (AstraZeneca and Eli Lilly) both in the UK and the USA. Originally a pharmacologist by training Amy subsequently studied for a PhD in Neuroscience where her research focussed on understanding the role of certain glutamate receptors in stroke. She also has a Masters degree in IP Law.